SCHEDULE: Goldman Sachs Discloses Minor Stake in 2SEVENTY BIO
Beneficial Ownership Disclosure
Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC reported a negligible 0.0% beneficial ownership in 2SEVENTY BIO, INC. common stock.
Summary
- The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, jointly filed an Amendment No. 1 to Schedule 13G.
- The filing discloses beneficial ownership of 308 shares of Common Stock, par value $0.0001 per share, in 2SEVENTY BIO, INC.
- This aggregate amount represents 0.0% of the issuer's class of securities.
- Goldman Sachs & Co. LLC holds shared voting power over 133 shares and shared dispositive power over 308 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a factual, routine disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or prospects.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This Schedule 13G filing is a routine disclosure by a large financial institution regarding its passive, non-controlling investment in a publicly traded company. It does not provide specific insights into broader industry trends or competitive dynamics, as its primary purpose is to report ownership percentages.
Stakeholder Impact
- Shareholders: Provides transparency regarding a minor, passive institutional ownership stake, which is unlikely to impact control or strategic direction.
Key Dates
| Date | Description |
|---|---|
| 2024-07-29 | Previous Power of Attorney granted by The Goldman Sachs Group, Inc. superseded by the new one. |
| 2024-10-01 | Previous Power of Attorney granted by Goldman Sachs & Co. LLC superseded by the new one. |
| 2025-06-30 | Date of event which required the filing of this statement. |
| 2025-07-16 | Date of execution for the new Power of Attorney by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC. |
| 2025-07-17 | Date of filing of this Schedule 13G Amendment No. 1. |
| 2026-07-16 | Expiration date of the current Power of Attorney, unless earlier revoked. |
Keywords
Goldman Sachs, 2SEVENTY BIO, Schedule 13G, beneficial ownership, common stock, institutional investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.